Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroko Bando

Showing results (101-110 of 126) with videos related to

Pageof 13
Sort By:
Breast Cancer Research and Treatment|May 20, 2024
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)Toshimi Takano, Norikazu Masuda, Mitsuya Ito, et al.
Cancers|August 27, 2021
Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)Eriko Tokunaga, Norikazu Masuda, Naohito Yamamoto, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 2, 2025
Tumor-expressed GPNMB orchestrates Siglec-9<sup>+</sup> TAM polarization and EMT to promote metastasis in triple-negative breast cancerThuy Linh Dang Cao, Kunio Kawanishi, Sachie Hashimoto, et al.
Contemporary Clinical Trials Communications|November 17, 2022
Effectiveness of an online support program to help female cancer patients manage their health and illness: Protocol for a randomized controlled trialMichiyo Mizuno, Ikuko Chiba, Toru Mukohara, et al.
The Lancet. Oncology|June 20, 2025
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trialMitsue Saito, Hirotoshi Iihara, Mototsugu Shimokawa, et al.
BMC Medicine|April 25, 2022
Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TRTakayuki Ueno, Shigehisa Kitano, Norikazu Masuda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2021
Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast CancerNaruto Taira, Masataka Sawaki, Yukari Uemura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2020
Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older PatientsMasataka Sawaki, Naruto Taira, Yukari Uemura, et al.
Lab on a Chip|January 17, 2023
Virtual-freezing fluorescence imaging flow cytometry with 5-aminolevulinic acid stimulation and antibody labeling for detecting all forms of circulating tumor cellsHiroki Matsumura, Larina Tzu-Wei Shen, Akihiro Isozaki, et al.
Breast Cancer Research and Treatment|March 25, 2021
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trialNorikazu Masuda, Hiroko Bando, Takashi Yamanaka, et al.
Pageof 13

Showing results (101-110 of 126) with videos related to

Sort By:
Pageof 13
Breast Cancer Research and Treatment|May 20, 2024
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)Toshimi Takano, Norikazu Masuda, Mitsuya Ito, et al.
Cancers|August 27, 2021
Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)Eriko Tokunaga, Norikazu Masuda, Naohito Yamamoto, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 2, 2025
Tumor-expressed GPNMB orchestrates Siglec-9<sup>+</sup> TAM polarization and EMT to promote metastasis in triple-negative breast cancerThuy Linh Dang Cao, Kunio Kawanishi, Sachie Hashimoto, et al.
Contemporary Clinical Trials Communications|November 17, 2022
Effectiveness of an online support program to help female cancer patients manage their health and illness: Protocol for a randomized controlled trialMichiyo Mizuno, Ikuko Chiba, Toru Mukohara, et al.
The Lancet. Oncology|June 20, 2025
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trialMitsue Saito, Hirotoshi Iihara, Mototsugu Shimokawa, et al.
BMC Medicine|April 25, 2022
Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TRTakayuki Ueno, Shigehisa Kitano, Norikazu Masuda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2021
Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast CancerNaruto Taira, Masataka Sawaki, Yukari Uemura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2020
Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older PatientsMasataka Sawaki, Naruto Taira, Yukari Uemura, et al.
Lab on a Chip|January 17, 2023
Virtual-freezing fluorescence imaging flow cytometry with 5-aminolevulinic acid stimulation and antibody labeling for detecting all forms of circulating tumor cellsHiroki Matsumura, Larina Tzu-Wei Shen, Akihiro Isozaki, et al.
Breast Cancer Research and Treatment|March 25, 2021
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trialNorikazu Masuda, Hiroko Bando, Takashi Yamanaka, et al.
Pageof 13